Class Action Lawsuit Filed Against Merck & Co. – Important Deadline Approaching for Shareholders

Overview of the Class Action Against Merck & Co., Inc.

On March 27, 2025, The Gross Law Firm announced a class action lawsuit against Merck & Co., Inc. (NYSE: MRK), senior stakeholders of which are alerted to the impending deadline for participation in this legal action. Shareholders who invested in MRK during the specified class period from February 3, 2022, to February 3, 2025, are being encouraged to reach out to the firm. This is crucial for anyone aiming for a lead plaintiff role, although taking on this responsibility is not necessary to receive any form of recovery. The deadline to register is April 14, 2025.

Allegations Against Merck

The allegations against Merck revolve primarily around misleading information disseminated to investors regarding the company's future revenue expectations from sales of Gardasil, a vaccine designed to prevent certain types of human papillomavirus (HPV). According to the complaint, Merck claimed they anticipated generating $11 billion in revenue from Gardasil sales by the year 2030. This forecast was backed by assertive statements that the company was poised to enhance demand through robust consumer education and activation initiatives, particularly aimed at the Chinese market.

However, the situation took a significant downturn on February 4, 2025, when Merck announced they would halt Gardasil shipments to China for at least part of the year. This decision stemmed from an urgent need to cut down on inventory levels due to unexpectedly low demand, contradicting prior optimistic projections. As a direct consequence of this news, Merck's stock plummeted from a closing price of $99.79 on February 3, 2025, to $90.74 the following day, marking a drastic decline of over 9% within a mere 24-hour period. This sudden drop has intensified scrutiny on Merck’s revenue forecasts and strategic decisions concerning Gardasil.

Next Steps for Affected Shareholders

Shareholders who purchased MRK stock within the class period should not delay in registering for this class action. Upon registration, individuals will gain access to a portfolio monitoring tool, which provides real-time updates on the status of the case throughout its duration. Notably, participation in this class action comes at no financial obligation or cost to the shareholders. Furthermore, even if individuals do not aspire to be lead plaintiffs, their involvement is welcomed to ensure a comprehensive representation of affected investors.

For additional information and to register, shareholders can visit the following link: Merck Shareholder Registration.

Conclusion

The Gross Law Firm is committed to defending the rights of investors who suffer losses due to misleading or false claims by corporations. They aim to hold companies accountable for their actions and ensure responsible business practices are upheld. As this class action progresses, it will serve as a vital avenue for shareholders of Merck & Co., Inc. to seek justice and possibly recover some of their losses incurred during the alleged misrepresentation of the company’s revenue expectations concerning Gardasil.

For inquiries, shareholders are encouraged to contact The Gross Law Firm directly at their New York office.

Contact Details:
The Gross Law Firm
15 West 38th Street, 12th Floor
New York, NY 10018
Email: [email protected]
Phone: (646) 453-8903